Lupin Receives EIR from U.S. FDA for its Aurangabad (CSN) Facility

Global pharma major Lupin Limited (Lupin) today announced that it has received the Establishment Inspection Report (EIR) from the United States Food and Drug Administration (U.S. FDA) for its Chhatrapati Sambhajinagar (Aurangabad) facility, following a product-specific Pre-Approval Inspection from September 1 to September 5, 2025.

Nilesh Gupta, Managing Director, Lupin said, "We are pleased to have received the EIR from the U.S. FDA for our Aurangabad facility. This underscores our commitment to upholding the highest standards of quality and compliance, and delivering trusted healthcare solutions to patients worldwide."

Shares of Lupin Limited was last trading in BSE at Rs. 2035.85 as compared to the previous close of Rs. 1975.70. The total number of shares traded during the day was 17455 in over 1695 trades.

The stock hit an intraday high of Rs. 2040.00 and intraday low of 1974.90. The net turnover during the day was Rs. 35182301.00.

Source : Equity Bulls

Keywords

Lupin INE326A01037 Pharmaceuticals USFDA EIR AurangabadFacility